Tenax Therapeutics Q2 2026: $17.8M Net Loss, $118M Cash, LEVEL Data Due August
$118.0 million in cash and cash equivalents sat on Tenax Therapeutics' (Nasdaq: TENX) balance sheet at June 30, 2026, up from $97.6 million at December 31, 2025, with $13.4 million of the gain from warrant exercises during the quarter…
By Sabrina Volkov·Jul 31, 2026·2 min read·regulatory·TENX
Source: sec.gov
© 2026 NewsMeter
Regulatory · PARASep 12, 2026
Banzai International prices $2,142,857 convertible note with 30% OID, $1.5M clearing at first close
2 min
RegulatorySep 12, 2026
Fan brawl inside Los Angeles Cosm theater surfaces as immersive venue prices run 6.9x the stadium gate
2 min
Regulatory · QBTSSep 10, 2026
D-Wave Quantum registers 7.1 million U.S. Commerce Department shares for resale
1 min